Maravai LifeSciences Holdings, Inc. MRVI Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Maravai LifeSciences Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Maravai LifeSciences Holdings, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Maravai LifeSciences Holdings, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Maravai LifeSciences Holdings, Inc.'s stock-based comp?
- Maravai LifeSciences Holdings, Inc. (MRVI) reported stock-based comp of $6.74M in Q1 2026.
- How has Maravai LifeSciences Holdings, Inc.'s stock-based comp changed year-over-year?
- Maravai LifeSciences Holdings, Inc.'s stock-based comp decreased by 35.2% year-over-year, from $10.4M to $6.74M.
- What is the long-term trend for Maravai LifeSciences Holdings, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Maravai LifeSciences Holdings, Inc.'s stock-based comp has grown at a 30.3% compound annual growth rate (CAGR), from $10.46M to $30.17M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.